The tweet was deleted by the author.
But we saved everything 🙂.
Zymeworks marked Lung Cancer Awareness Day by recognizing the millions of people affected by lung cancer.
The company stated its commitment to advancing next-generation therapeutics designed to improve treatment options. Details are being clarified.
View post on X Loading...
ZYME is trading at $21.94, positioned below the MA-20 ($24.19), MA-50 ($24.24), and MA-200 ($23.98), reflecting persistent downside pressure across all timeframes. The Ichimoku Kijun level at $24.61 sits above the current price, serving as immediate resistance; nearest support is identified at the MA-200 ($23.98), while the MA-100 at $24.96 and Kijun at $24.61 mark key resistance above, with additional near-term support from the MA-200 and key support at the W1 MA-100 ($19.22).
Momentum remains weak, with MACD on D1 in sell territory and an ADX reading of 18.17 indicating lack of direction; meanwhile, oscillators such as RSI (35.59), Stoch RSI (17.65), and CCI (-117.89) show oversold conditions, suggesting the stock is nearing exhaustion on the downside. BBP at -0.47 confirms that sellers dominate intraday dynamics. ZYME has fallen $0.92 (4.02%) over the past week, opening at $22.86 and closing at the very bottom of the weekly range, as weekly volatility stands at 8.16%. The tone for the week is firmly bearish, with price action steadily declining from the high; in today's session, ZYME is down 3.39%, accelerating the move toward weekly support.
Looking ahead, the expected price range for the next week is $20.95 to $24.01, adjusted to remain within 10% of the current level and anchored between the 52-week low of $11.51 and high of $29.75. Based on W1 indicators—RSI (Sell), MA-50 (Sell), ADX (Buy), and MACD (Strong Buy)—the probability of a price increase is average (about 50%), with downside risk equally likely. The baseline scenario suggests ZYME will consolidate within this corridor. A bullish break above $24.01 resistance would open room for recovery toward higher moving averages, while a bearish breach below $20.95 support could trigger a retest toward deeper weekly support levels.
Previously it was reported that Zymeworks was experiencing sustained downside pressure, with technical indicators signaling a lack of near-term rebound momentum. As the current market environment evolves, investors should monitor for a potential shift in sentiment that could trigger either a renewal of downward trends or the start of a recovery phase.